Buy Emami, says Rajesh Jain, Market Strategist.
Jain told CNBC-TV18, "Emami would be an interesting buy on an intraday basis for a target of Rs 510. The company has just announced a foray into the nutraceuticals market this would further strengthen its personal healthcare and pharma products, which is largely based on an Ayurvedic platform.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
